Skip to content
The Policy VaultThe Policy Vault

Purified Cortrophin GelUnited Healthcare

Ophthalmic diseases

Initial criteria

  • ONE of the following: Rheumatic disorders (psoriatic arthritis, rheumatoid arthritis incl. juvenile, ankylosing spondylitis, acute gouty arthritis)
  • OR Collagen diseases (systemic lupus erythematosus or systemic dermatomyositis/polymyositis)
  • OR Dermatologic diseases (severe erythema multiforme/Stevens-Johnson syndrome or severe psoriasis)
  • OR Allergic states (atopic dermatitis or serum sickness)
  • OR Ophthalmic diseases (severe acute/chronic allergic or inflammatory processes of the eye such as allergic conjunctivitis, keratitis, iritis/iridocyclitis, diffuse posterior uveitis/choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation)
  • OR Respiratory diseases (symptomatic sarcoidosis)
  • OR Edematous states (to induce diuresis or remission of proteinuria in nephrotic syndrome without uremia of idiopathic or lupus etiology)

Reauthorization criteria

  • Documentation of positive clinical response to Purified Cortrophin Gel therapy

Approval duration

12 months